+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Essential thrombocythemia with JAK2 V617F mutation transformed into acute myeloid leukemia without JAK2 V617F mutation:case report and literature review



Essential thrombocythemia with JAK2 V617F mutation transformed into acute myeloid leukemia without JAK2 V617F mutation:case report and literature review



Zhonghua Xue Ye Xue Za Zhi 35(12): 1122-1123




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057795722

Download citation: RISBibTeXText

PMID: 25543711


Related references

Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article. Medicine 97(27): E11331, 2018

JAK2 V617F positive mutation transformed to calreticulin mutation in one patient with essential thrombocythemia. Zhonghua Xue Ye Xue Za Zhi 38(1): 38, 2018

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110(1): 375-379, 2007

A case of minor BCR-ABL1 positive acute lymphoblastic leukemia following essential thrombocythemia and originating from a clone distinct from that harboring the JAK2-V617F mutation. Experimental Hematology and Oncology 3(1): 6, 2014

Disappearance of JAK2 V617F mutation in a rapid leukemic transformed essential thrombocythemia patient. Leukemia Research 32(8): 1323-1324, 2007

Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up. Oncology Letters 12(1): 485-487, 2016

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 116(9): 1528-1538, 2010

Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment. American Journal of Hematology 82(6): 500-501, 2007

Simultaneous presentation of JAK2 V617F mutation-related essential thrombocythemia and B-cell chronic lymphocytic leukemia. Blood Research 49(2): 134-137, 2014

JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report. Acta Haematologica 129(1): 23-25, 2013

Familial Essential Thrombocythemia Associated with MPL W515L Mutation in Father and JAK2 V617F Mutation in Daughter. Case Reports in Hematology 2014: 841787, 2014

Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide. Leukemia and Lymphoma 58(10): 2511-2513, 2017

Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genetics 208(11): 571-574, 2016

Evaluation of JAK2(V617F) in B and T cell neoplasms: Identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals. Acta Haematologica (Basel) 118(4): 209-214, 2007

Myelodysplastic syndrome with del (5q) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with complex karyotype. Annals of Hematology 95(3): 525-527, 2016